Not every life science company is at the same buying stage when they start researching SEO pricing. Understanding where you sit shapes what scope — and what budget — is actually appropriate.
Early-Stage Biotechs and Startups
If you're pre-commercial, your SEO goals are typically investor visibility, partnership discovery, and scientific credibility. You don't need a $12,000/month program. A focused engagement covering technical foundations, a thought leadership content strategy, and targeted keyword ownership in your therapeutic area can start lower and scale as you grow.
Commercial-Stage Pharma and Specialty Pharma
Once you're marketing approved products — directly to HCPs, patients, or payers — the complexity increases substantially. Regulatory review cycles slow content production. Multiple audience segments require separate content tracks. Compliance with FDA promotional guidelines and platform-specific rules adds overhead to every deliverable. This is where mid-to-upper-tier budgets become necessary, not optional.
Medtech and Diagnostics Companies
Medtech SEO often requires balancing clinical evidence content (for HCP audiences) with product-oriented content (for procurement and hospital administration). If your product has CPT codes or reimbursement documentation, that content layer adds meaningful scope. Companies with multiple product lines across different specialties typically need broader programs than single-device companies.
CROs and Life Science Service Providers
Contract research organizations, CDMOs, and other B2B service providers in the life science space have a different challenge: competing for high-intent service queries against large incumbents. SEO here is primarily about content authority in niche methodology areas and technical site performance — both of which are well-defined scope items that agencies can price clearly.
The honest answer is that the right budget depends on your growth stage, your audience, and how competitive your target keywords are. A pre-IND biotech and a commercial pharma company operating in the same therapeutic area are not buying the same thing.